Pfizer reported stronger-than-expected first-quarter earnings and revenue, with adjusted earnings per share at 75 cents, surpassing the 72 cents forecast, and revenue of $14.45 billion, exceeding expectations of $13.79 billion. The pharmaceutical giant reaffirmed its 2026 outlook, buoyed by growth from newly launched and acquired products, notably its recent $10 billion acquisition of obesity biotech Metsera.
This performance is significant as it highlights Pfizer’s strategic pivot away from declining Covid product sales and older drugs, focusing instead on innovative therapies and long-term investments. The company is also gearing up for critical data releases this year, including late-stage trial results for a targeted lung cancer drug, which could further influence its market position and investor sentiment.
Investors should note that Pfizer’s ability to navigate the post-Covid landscape and successfully integrate its acquisitions will be crucial for sustaining growth and maintaining stock performance in the coming quarters.
Source: cnbc.com